How Are Payers Controlling Costs With New Hepatitis C Treatments?

The recent growth of Hepatitis C treatment, now has payers considering the HCV category right up there with cancer, rheumatoid arthritis, and multiple sclerosis. Take a look at the recent approval of new hepatitis C treatments in Specialty Pharmacy Times’, Keeping an Eye on Hepatitis C Virus Drug Approvals, available here. (Source: :Lee Goldberg, Specialty Pharmacy Times, 8/20/14).

You might also be interested in:

Market Access Impact: Rheumatoid Arthritis (US) 2017 January 15, 2018
Syndicated Reports Spotlight RA, Type 2 Diabetes Mellitus January 15, 2018
Relentless Health Value’s Richter, #HCBiz Show!’s… August 2, 2018
CMPI VP: Fixing Health Care, Ending Economic Injustice October 25, 2017
Study: ICER Value Assessments Could Leave Medicare Part B… June 2, 2018
Dems, Multiple Sclerosis Activists Target High Drug Prices September 28, 2017
Pharmacy Times, Specialty Pharmacy Times Earn Hermes Creative Awards June 1, 2018